Hikal Ltd. News and Updates

Name: Latest research reports of Hikal Ltd. authored by BP Wealth and published by - Trendlyne research reports.
Item: Hikal Ltd.
Rating: 1
Author: BP Wealth

Keep track of all breaking news on Hikal Ltd. from all sources in a single place.

Load latest

Hikal Ltd.

07 May 2021

389.20

-2.32%

Hikal Consolidated March 2021 Net Sales at Rs 532.46 crore, up 40.49% Y-o-Y

Moneycontrol

NULL

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

05 May 2021

389.20

-2.32%

Hikal in 10-year multi-product deal with global player

Business Line

To develop and supply APIs from Panoli plant; stock hits upper circuit

Hikal Ltd. is trading above all available SMAs

Hikal hits upper circuit after it signs a multi-year deal

Economic Times | 05 May 2021 1 more

Hikal Ltd.

17 Apr 2021

389.20

-2.32%

Trading pick of the week: Hikal (179.6): Buy

Business Line

Investors with a medium-term perspective can buy the stock of Hikal, a small-cap pharmaceuticals company, at current levels. The company offers solut

Hikal Ltd. has an average target of 420.00 from 1 broker.

Hikal Ltd.

04 Feb 2021

389.20

-2.32%

Hikal Consolidated December 2020 Net Sales at Rs 463.29 crore, up 14.66% Y-o-Y

Moneycontrol

NULL

Hikal Ltd. has gained 29.91% in the last 1 Year

Hikal's profit after tax rises 42.8% to Rs 40 crore in December quarter

Business Standard | 04 Feb 2021

Hikal Ltd.

03 Dec 2020

389.20

-2.32%

Why should investors look at Hikal?

Moneycontrol

One of the key aspects we like about Hikal is its efforts towards operational risk management

Hikal Ltd. has gained 29.91% in the last 1 Year

Hikal Ltd.

07 Nov 2020, 12:52PM

389.20

-2.32%

Buy Hikal; target of Rs 230: ICICI Direct

Moneycontrol

ICICI Direct is bullish on Hikal has recommended buy rating on the stock with a target price of Rs 230 in its research report dated November 05, 2020.

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

06 Nov 2020

389.20

-2.32%

BP Equities Hikal Ltd Q2FY21 Result Update

Sell: Hikal Ltd.

BP Wealth

INR3,368mn mainly driven by strong growth in the Pharmaceutical segment. On segmental performance: The crop protection segment de grew by 17.9% (YoY) to INR 926mn and 12.7% (YoY) due to deferment of orders worth INR400mn which is expected to be supplied largely in Q3FY21. Pharmaceutical segment revenue surged by 34.1% to INR 2,793mn led by strong volume off-take supported by new capacity at Bangalore unit which was commissioned late last year. Despite 554bps contraction in gross margin, EBITDA margin managed to improve by 58bps to18.8%, was 29bps above our estimate. EBITDA margin was supported by 11% (YoY) decline in employee cost and flat other expenses in the growing topline. EBIT margin of the Crop protection segment declined by 1044bps...

Hikal Ltd. has gained 29.91% in the last 1 Year

Hikal Ltd.

05 Nov 2020

389.20

-2.32%

Hikal Ltd

Buy: Hikal Ltd.

Target

ICICI Securities Limited

Q2FY21 revenues grew a decent 15.8% YoY to | 372 crore on the back of 34.1% YoY growth in pharma segment to | 279 crore. Crop protection segment fell 17.9% YoY to | 93 crore due to deferral of | 40 crore worth of shipment to Q3FY21. EBITDA for the quarter came in at | 70 crore, up 19.6% YoY (including Covid related expenses of | 1.1 crore). EBITDA margins expanded 58 bps YoY to 18.8% due to lower staff & other expenses, partly offset by lower gross margins. Adjusted PAT grew 23.8% YoY to | 27 crore in line with operational performance. Delta vis-a-vis EBITDA was due to...

Hikal Ltd. has gained 29.91% in the last 1 Year

Hikal Ltd.

17 Sep 2020

389.20

-2.32%

Hikal (183): Buy

Business Line

The stock of Hikal jumped 9.3 per cent accompanied by extra-ordinary volume on Thursday, breaking above a key short-term resistance at 175. This rall

Hikal Ltd. has gained 29.91% in the last 1 Year

Hikal shares advance 12%, hit 52-week high on growth prospects

Business Standard | 17 Sep 2020

Hikal Ltd.

08 Sep 2020, 09:56AM

389.20

-2.32%

Hikal: Focus on operational risk management adds to conviction

Moneycontrol

Any protectionist measure from the government, given the recent trend towards ant-dumping duty and Make in India theme could disproportionately benefit the Hikal